Mundipharma Welcomes the New Guidelines from ESC/EASD Recommending First-Line use of Sodium-Glucose Co-transporter-2 Inhibitors for Type 2 Diabetes Patients with Cardiovascular Disease
As the European distributor of Invokana® (canagliflozin) and Vokanamet® (canagliflozin and metformin), the Mundipharma network of independent associated companies welcomes the news that the sodium-glucose co-transporter-2 inhibitor (SGLT2i) class, which includes canagliflozin, has now been recommended in the newly published 2019 ESC (European Society of Cardiology) Guidelines on Diabetes, Pre-Diabetes and Cardiovascular Diseases developed in collaboration with the EASD (European Association for the Study of Diabetes) as a first-line treatment option for the management of patients with type 2 diabetes mellitus (T2DM), either drug naïve or on metformin, with atherosclerotic cardiovascular disease (ASCVD) or high/very high cardiovascular (CV) risk, which includes patients with other target organ damage (i.e. damage to the kidneys as predicted by important markers such as proteinuria and eGFR) and multiple other risk factors.1 Furthermore, SGLT2is are also recommended as a first-line treatment for patients with T2DM at high risk of heart failure (HF).1 The new guidelines were presented yesterday at the 2019 ESC Congress in Paris, France and have been published in the European Heart Journal.1
The updated guidelines took into account data from CV outcomes trials for SGLT2is which have demonstrated a range of CV benefits across the class. This includes the positive CV outcomes data for canagliflozin from the CANVAS Programme.2
The guidelines now recommend SGLT2is as a first-line treatment option for the prevention and management of chronic kidney disease (CKD) for patients with T2DM, who have a high associated risk of CV disease.1 Nephroprotection has been observed in recent CV outcome trials, including the CREDENCE study, which found canagliflozin plus standard of care reduced the relative risk of the primary renal and cardiovascular outcomes compared with placebo plus standard of care.3 Canagliflozin is currently under review by the European Medicines Agency (EMA) to extend its licence for use in the T2DM with CKD patient population.
“It is exciting to see that the recent positive results from CV outcomes trials of SGLT2is in patients with type 2 diabetes have been reflected in the updated ESC/EASD guidelines,” commented Professor Antonio Ceriello, Head of Diabetes Research Department, IRCCS MultiMedica, Milan, Italy. “It is important for clinicians to now recognise that initiating an SGLT2i, such as canagliflozin, as a first line therapy in patients with certain types of CV disease, or target organ damage, may improve long-term patient outcomes.”
Approximately 58 million people in Europe currently live with T2DM, which is set to rise to 67 million by 2045.5 If left untreated, patients are at greater risk of developing serious health complications, such as renal disease, HF, and CV disease which is the most common cause of death for T2DM patients.4
“Cardiovascular disease is a major complication of type 2 diabetes which puts patients’ lives at risk and is a significant burden on healthcare systems across Europe. With the new guidelines, clinicians can make the best treatment decisions and transform the standard of care for their patients.” said Dr Vinicius Gomes de Lima, European Medical Affairs Lead, Mundipharma.
The updated guidelines can be viewed at: https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Diabetes-Pre-Diabetes-and-Cardiovascular-Diseases-developed-with-the-EASD.
Notes to the editors:
About the Guidelines1
The European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD) convened a panel to update the existing guidelines, published in 2013, on the management of diabetes, pre-diabetes and cardiovascular diseases. The updated guidelines were published in the European Heart Journal and were presented during the annual meeting of ESC in Paris, France, on the 2nd September 2019.
Invokana® (canagliflozin) is an oral, once-daily medication which belongs to a class of medications called sodium glucose co-transporter 2 (SGLT2) inhibitors. SGLT2 inhibitors work by inhibiting SGLT2, which promotes the loss of glucose via the urine, lowering blood glucose levels in adults with T2DM. Invokana was approved in the European Union by the European Commission in November 2013. It is indicated for the treatment of adults with insufficiently controlled T2DM as an adjunct to diet and exercise, as monotherapy when metformin is considered inappropriate due to intolerance or contraindications and in addition to other medicinal products for the treatment of diabetes. Approval was based on a comprehensive global Phase III clinical trial programme.
Vokanamet® (a fixed-dose combination of canagliflozin and metformin) is approved in the European Union for the treatment of adults with insufficiently controlled type 2 diabetes as an adjunct to diet and exercise. Vokanamet combines two oral glucose-lowering medicinal products with different and complementary mechanisms of action.
About the CANVAS Programme2
The CANVAS Programme (N=10,142) comprised the two large canagliflozin cardiovascular outcome trials, CANVAS and CANVAS-R, and included a pre-specified integrated analysis of these two studies to evaluate the potential for CV protection of canagliflozin in patients with T2DM who had either a prior history of CV disease or at least two CV risk factors. The integrated analysis also evaluated the effects of canagliflozin on renal and safety outcomes.
Canagliflozin met the primary outcome by significantly reducing the rates of the composite of major adverse CV events (MACE) comprised of CV mortality, non-fatal myocardial infarction (MI), or non-fatal stroke (26.9 vs. 31.5/1000 patient-years, hazard ratio (HR) 0.86; 95% confidence interval (CI 0.75-0.97; P<0.0001 for non-inferiority; P=0.0158 for superiority) compared with placebo plus standard of care, respectively. All 3 components of MACE composite (CV death, non-fatal MI, and non-fatal stroke) exhibited point estimates of effect suggesting benefit with canagliflozin.
Adverse events reported in the CANVAS Programme were generally consistent with the known safety profile of canagliflozin. Whilst an increase in lower limb amputation and bone fractures were observed in the CANVAS Programme, this signal was not observed in further long term clinical trial data involving high risk patients.3
About the CREDENCE Clinical Trial3
The CREDENCE (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation) study was the first dedicated and fully recruited renal outcome trial evaluating renal and cardiovascular outcomes in people with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) with a sodium glucose co-transporter 2 (SGLT2) inhibitor. It was a phase 3 randomised, double-blind, event-driven, placebo-controlled, parallel-group, 2 arm multi-centre study of the effects of canagliflozin on renal and cardiovascular outcomes in subjects with T2DM and CKD. In particular, it compared the efficacy and safety of canagliflozin versus placebo at preventing clinically important kidney and cardiovascular outcomes in patients with T2DM and CKD when used in addition to standard of care, including a maximum tolerated daily dose of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB).
About the Mundipharma network
Mundipharma is a global network of privately-owned independent associated companies whose purpose is to move medicine forward. With a high performing and learning organisation that strives for innovation and commercial excellence through partnerships, we successfully transformed and diversified our European portfolio of medicines to create value for patients, payers and wider healthcare systems across important therapeutic areas such as Diabetes, Respiratory, Oncology, Pain and Biosimilars.
Invokana® and Vokanamet® are registered trademarks of Janssen
1 European Society of Cardiology (ESC). 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal (2019);00,1-69.
2 Neal B et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. The New England Journal of Medicine (2017);377:644-657.
3 Perkovic, V. et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephrology. The New England Journal of Medicine. 2019; 380(24): 2295-2306.
4 Fan, W. Epidemiology in diabetes mellitus and cardiovascular disease. Cardiovascular Endocrinology & Metabolism. 2017;6(1):8-16.
5 IDF Diabetes Atlas Eighth Edition 2017. Available at: http://diabetesatlas.org/resources/2017-atlas.html. Last accessed September 2019.
6 Invokana SmPC. Available at: https://www.ema.europa.eu/en/documents/product-information/invokana-epar-product-information_en.pdf Last accessed September 2019
7 Vokanamet SmPC. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/SGLT2_inhibitors 20/European_Commission_final_decision/WC500206514.pdf. Last accessed September 2019
Job code: MBL/DIAB-19025
Date of preparation: September 2019
Asset Communications Associate, Mundipharma International Ltd
Tel: +44 (0) 1223 393 009
Senior Account Manager, Havas SO
Tel: +44 (0) 20 3196 9919
Mob: +44 7375 660 515
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ISACA Combines EuroCACS and CSX Conferences for the First Time in ISACA’s 50th Anniversary Year17.9.2019 14:15:00 CEST | Press release
Digital transformation and emerging technologies are the focus of ISACA’s combined EuroCACS/Cybersecurity Nexus (CSX) conference in Geneva, Switzerland, from 16-18 October 2019, as ISACA continues celebrating its 50th anniversary year. Sessions focused on DevOps, Agile, cryptocurrency, mobile payments, the Internet of Things (IoT), and other hot topics will bring together business technology professionals who lead information systems audit, risk, governance and security functions at their enterprises. Keynote speaker Anders Sorman-Nillson, a global futurist and innovation strategist, will open EuroCACS/CSX, and entrepreneur Jon Duschinsky, who was voted the second-most influential communicator in social innovation, will deliver the closing keynote. Also planned is a general-session panel to mark ISACA’s 50th anniversary in 2019 that features industry experts in innovation and a concurrent general session on “The Weaponisation of the IoT.” Attendees can advance their skills across techn
Andersen Global Expands in Rwanda17.9.2019 13:30:00 CEST | Press release
Andersen Global announced today a collaboration agreement with MRB Attorneys in Rwanda. The addition of the Kigali-based firm marks the 16th country with a presence in Africa for Andersen Global. MRB Attorneys was founded in 2013 by the firm’s five partners, who all have extensive experience in private and public legal consultancy services. Today, MRB’s eleven attorneys advise clients in corporate and commercial law, dispute resolution, energy and infrastructure, and government business and policy, with a heavy emphasis on banking and investment issues. They represent a broad clientele of banks, private and public companies, international organizations, and government agencies. “Andersen Global’s reputation of stewardship and transparency lines up well with what our clients value and have come to expect from us. The synergetic collaboration will be beneficial for our clients and our people,” said Emmanuel Butare, MRB Attorneys’ Managing Partner. “We are excited to work with like-minded
Taiwan: Rising Importance of Proton Therapy and a Fortress for Cancer Treatment17.9.2019 13:15:00 CEST | Press release
There is no place like Taiwan where medical services are readily accessible with quality and efficiency, attracting nearly 500,000 patients worldwide annually and attention from dominant medical devices suppliers. Cancer treatment is one of medical specialties that Taiwan gains recognition in Asia. The focal point now goes to proton therapy, which is proven to be a painless way to deliver radiation dose in targeted tumours precisely and maintains side effects happening in the minimum level. Proton therapy key players race for Asia markets Despite proton therapy indicating a promising alternative for cancer treatments, it is far from close to a mainstream service that can be found in medical institutes. As per PTCOG statistics, there are 82 medical institutes to date having the therapy on offer, with one in operation and 9 to go in Taiwan- the highest density as opposed to the rest of the world. Chang Gung Memorial Hospital launched the service in 2015, followed closely by its peers inc
CE China 2019: The International Brand Show for Consumer and Home Electronics17.9.2019 13:13:00 CEST | Press release
For the first time, CE China - a global IFA event - is held from 19 to 21 September 2019 in Guangzhou, the heart of China's trade and manufacturing business. The new date in September is perfect for preparation of Singles Day and end of year business in Asia. CE China provides an ideal platform and comprehensive services for consumer electronics and home appliance brands. The show has successfully established partnerships with leading global retailer chains such as Suning and Alibaba’s Tmall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190917005728/en/ Autonomous driving and new mobility at CE China 2019 CE China 2019 includes Connected Driving and New Energy Vehicles section in its spectrum tackling the trend of autonomous driving. Today, intelligent interconnection is not only a major trend in household appliances and electronic consumer goods, but also key to the automotive industry – bringing consumer electronics, hou
Zscaler Extends Edge Compute, Now Operating in Over 150 Data Centers17.9.2019 13:00:00 CEST | Press release
Zscaler, Inc., the leader in cloud security, today announced the Zscaler™ platform is now distributed across over 150 data centers, with the company’s latest data center opening in Val-du-Roi, Normandy, France. The expansion is part of the company’s ongoing mission to provide enterprise users with fast, secure, reliable access to applications and services regardless of location, empowering enterprises to accelerate their cloud adoption, securely. Built on the Zscaler multi-tenant cloud architecture, the Zscaler platform unifies secure internet gateway services, cloud sandbox, next-generation cloud firewall, data loss prevention, SSL decryption, bandwidth control, and more, with simplified policy management and reporting. It is now distributed across more than 150 data centers on six continents, which enables users to access the internet and cloud services securely from any device, any location, and over any network. “The physical footprint and end-to-end control of the network, infrast
Quake Global Launches Global LTE as the Latest Innovation for Our Best-Selling Products, QPRO™ and Q4000™17.9.2019 13:00:00 CEST | Press release
Quake Global, Inc. is excited to announce the availability of global LTE in our best-selling products, QPRO™ and Q4000™, which both come with bi-directional and dual-mode communication protocols over global satellite and cellular networks. Q4000 and QPRO are now available to our customers across the globe featuring the latest LTE communication technology, Cat M1/NB-IoT. This technology is designed to support M2M markets with a special focus on lower data costs for IoT data-driven applications. LTE is ideal for our customers who have equipment spanning significant geographic areas. The robust hardware housing and platform are designed to withstand extreme weather conditions, challenging work environments and are built to last. “At Quake, we continually strive to bring the most advanced telecommunication technology to our customers to ensure connectivity to assets in every part of the world,” said Polina Braunstein, CEO and President of Quake Global. Quake’s QRO and Q4000 family of produ